The effects of PPAR-γ ligand pioglitazone on platelet aggregation and arterial thrombus formation

Cardiovascular Research

Volumn 65, Issue 4, 2005, Pages 907-912

  Li, Dayuan ^a   Chen, Kui ^a   Sinha, Nandita ^a   Zhang, Xingjiang ^a   Wang, Yin ^a   Sinha, Anjan K ^a   Romeo, Francesco ^c   Mehta, Jawahar L ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Arterial thrombosis; cNOS; PPAR agonist; Thrombomodulin

Indexed keywords

ARACHIDONIC ACID; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; THROMBOMODULIN;

ABDOMINAL AORTA; ANIMAL MODEL; AORTA FLOW; ARTICLE; BIOLOGICAL MONITORING; CONTROLLED STUDY; DOPPLER FLOWMETRY; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; ENZYME ACTIVATION; FEEDING; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANIMALS; AORTA; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; LIGANDS; MALE; NITRIC OXIDE SYNTHASE; PLATELET AGGREGATION; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; THIAZOLIDINEDIONES; THROMBOMODULIN; THROMBOSIS;

EID: 13844272374     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.11.027     Document Type: Article

References (30)

1. S.P. Marso, A.M. Lincoff, S.G. Ellis, D.L. Bhatt, J.F. Tanguay, and N.S. Kleiman Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy Circulation 100 1999 2477 2484
2. K. Aljabri, S.E. Kozak, and D.M. Thompson Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial Am. J. Med. 116 2004 230 235
3. M. Bajaj, S. Suraamornkul, T. Pratipanawatr, L.J. Hardies, W. Pratipanawatr, and L. Glass Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes Diabetes 52 2003 1364 1370
4. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 1992 879 887
5. O. Barbier, I.P. Torra, Y. Duguay, C. Blanquart, J.C. Fruchart, and C. Glineur Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 22 2002 717 726
6. J.L. Mehta, B. Hu, J. Chen, and D. Li Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation Arterioscler. Thromb. Vasc. Biol. 23 2003 2203 2208
7. S.T. de Dios, D. Bruemmer, R.J. Dilley, M.E. Ivey, G.L. Jennings, and R.E. Law Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation Circulation 107 2003 2548 2550
8. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.C. Fruchart Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 1998 2088 2093
9. B. Molavi, C. Rasouli, and J.L. Mehta PPAR ligands as anti-atherogenic agents: panacea or another Pandora's box J. Cardiovasc. Pharmacol. Ther. 7 2002 1 7
10. K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, and M.W. Baumstark Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study Diabetes Care 26 2003 2588 2594
11. N. Satoh, Y. Ogawa, T. Usui, T. Tagami, S. Kono, and H. Uesugi Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect Diabetes Care 26 2003 2493 2499
12. T.L. Yue, J. Chen, W. Bao, P.K. Narayanan, A. Bril, and W. Jiang In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone Circulation 104 2001 2588 2594
13. B. Molavi, and J.L. Mehta Cardioprotective effects of rosiglitazone against ischemia-reperfusion injury are associated with modulation of angiotensin receptor expression and signaling J. Am. Coll. Cardiol. 883-5 2004 305A [Abstract]
14. L.Y. Chen, P. Mehta, and J.L. Mehta Oxidized-LDL decreases l-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance in the effect of oxidized-LDL on platelet function Circulation 93 1996 1740 1746
15. D. Li, S. Weng, B. Yang, T. Saldeen, W.W. Nichols, and J.L. Mehta Inhibition of arterial thrombus formation by Apo-A-1-Milano Arterioscler. Thromb. Vasc. Biol. 19 1999 378 383
16. T. Saldeen, D. Li, and J.L. Mehta Differential effects of α- and γ-tocopherol on LDL oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis J. Am. Coll. Cardiol. 34 1999 1208 1215
17. C.N. Berry, G. Lassalle, C. Lunven, J.M. Altenburger, F. Guilbert, and A. Lalé SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity J. Pharmacol. Exp. Ther. 303 2002 1189 1198
18. J.L. Mehta, D.Y. Li, H.J. Chen, J. Joseph, and F. Romeo Inhibition of LOX-1 by statins may relate to upregulation of eNOS Biochem. Biophys. Res. Commun. 289 2001 857 861
19. J. Plutzky The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis Am. J. Cardiol. 92 2003 34J 41J
20. K. Schoonjans, G. Martin, B. Staels, and J. Auwerx Peroxisome proliferator-activated receptors, orphans with ligands and functions Curr. Opin. Lipidol. 8 1997 159 166
21. M. Ishibashi, K. Egashira, K. Hiasa, S. Inoue, W. Ni, and Q. Zhao Anti-inflammatory and anti-arteriosclerotic effects of pioglitazone Hypertension 40 2002 687 693
22. J.S. Welch, M. Ricote, T.E. Akiyama, F.J. Gonzalez, and C.K. Glass PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages Proc. Natl. Acad. Sci. U. S. A. 100 2003 6712 6717
23. Y. Hattori, M. Matsumura, and K. Kasai Vascular smooth muscle cell activation by C-reactive protein Cardiovasc. Res. 58 2003 186 195
24. T. Ishizuka, S. Itaya, H. Wada, M. Ishizawa, M. Kimura, and K. Kajita Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism Diabetes 47 1998 1494 1500
25. S. Kanaya, H. Ikeda, N. Haramaki, T. Murohara, and T. Imaizumi Intraplatelet tetrahydrobiopterin plays an important role in regulating canine coronary arterial thrombosis by modulating intraplatelet nitric oxide and superoxide generation Circulation 104 2001 2478 2484
26. M.M. Solis, M. Vitti, J. Cook, D. Young, C. Glaser, and D. Light Recombinant soluble human thrombomodulin: a randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model Thromb. Res. 73 1994 385 394
27. M. Lorenz, S. Wessler, E. Follmann, W. Michaelis, T. Dusterhoft, and G. Baumann A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation J. Biol. Chem. 279 2004 6190 6195
28. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells Arterioscler. Thromb. Vasc. Biol. 23 2003 52 57
29. D.H. Cho, Y.J. Choi, S.A. Jo, and I. Jo Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways J. Biol. Chem. 279 2004 2499 2506
30. H. Kanehara, G. Tohda, K. Oida, J. Suzuki, H. Ishii, and I. Miyamori Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone Thromb. Res. 108 2002 227 234